source
- AstraZeneca reports Phase 3 trial shows Imfinzi-Padcev combo improves survival in bladder cancerAstraZeneca announced that its Phase 3 study of the immunotherapy Imfinzi combined with the antibody‑drug conjugate Padcev, developed with Pfizer and Astellas, extended overall survival for patient…
- Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypesIbrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes. Data reveal that patients, including those with TP53 mutations, maint…